Answers are grounded in this paper and cite their sources.
Since the emergence of the Coronavirus disease 2019 (COVID-19) in Dec 2019, the world continues to be facing a fierce pandemic characterized by multiple waves at various paces in different countries. Globally, a fourth wave had started in the last quarter of 2021. As of 19 December, over 273 million cases and over 5.3 million deaths have been reported globally [ 1 ]. Since the causative agent of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an RNA virus, the virus is subject to a significant number of mutations overtime. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures [ 2 ].. The Omicron variant was reported to world health organization (WHO) from South Africa (SA) on 24 November 2021 [ 3 ] and promptly classified as a variant of concern on 26 November 2021 [ 2 ] (Table 1 ). One of the most concerning features of the Omicron variant is the aggregation of 50 mutations, of which about 30 mutations were detected in the spike protein [ 4 , 5 ]. These mutations are widely allocated at several proteins including NSP3, NSP4, NSP5, NSP6, NSP12, NSP14, S protein, envelope protein, membrane protein, and nucleocapsid protein [ 6 ]. However, the most feared mutations are those on the receptor-binding domain (RBD). The deletion in the S protein of (Δ69–70) is being used as a proxy for the detection of the omicron variant. This deletion gives a negative S gene but positive SARS-CoV-2 on the TaqPath PCR test [ 7 ].
No takes yet. Share an insight, caveat, or question.
Al‐Tawfiq et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: